COST OF BEST SUPPORTIVE CARE FOR NON-SMALL CELL LUNG CANCER PATIENTS - A GERMAN PERSPECTIVE

被引：1
|
作者：
Schmidt, U. [1 ]
Lipp, R. [2 ]
Drechsler, M. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[2] GermanOncol, Hamburg, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2244
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN86
引用
收藏
页码：A629 / A629
页数：1
相关论文
共 50 条
  • [31] An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer
    Araujo, A.
    Parente, B.
    Sotto-Mayor, R.
    Teixeira, E.
    Almodovar, T.
    Barata, F.
    Queiroga, H.
    Pereira, C.
    Pereira, H.
    Negreiro, F.
    Silva, C.
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2008, 14 (06) : 803 - 827
  • [32] The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
    Evans, WK
    LeChevalier, T
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (13) : 2249 - 2255
  • [33] Surviving Metastatic Non-Small Cell Lung Cancer - Experience and Supportive Care Needs of Patients Receiving Novel Therapies
    Heynemann, S.
    Lai-Kwon, J.
    Flore, J.
    Dhillon, H.
    Duffy, M.
    Burke, J.
    Briggs, L.
    Leigh, L.
    Mileshkin, L.
    Solomon, B.
    Ball, D.
    Kokanovic, R.
    Jefford, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S468 - S468
  • [34] ASSESSING THE UTILIZATION OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS
    Ruban, C.
    Blanchette, C. M.
    Howden, R.
    Kowalkowski, M.
    Marino, J.
    Saunders, W.
    VALUE IN HEALTH, 2017, 20 (09) : A511 - A511
  • [35] The role of chemotherapy (CT) and supportive care (SQ) in advanced non-small cell lung cancer (NSCLQ)
    Thatcher, N
    LUNG CANCER, 2002, 38 : S71 - S73
  • [36] Summary of the best evidence for prehabilitation management of patients with non-small cell lung cancer
    Wu, Wenfang
    Li, Huayan
    Fan, Rongrong
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2024, 11 (07)
  • [37] Phase III study of paclitaxel (Taxol®) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC)
    Thatcher, N
    Ranson, M
    Anderson, H
    Burt, P
    Davidson, N
    Nicolson, M
    Falk, S
    Carmichael, J
    Washington, T
    Jeynes, A
    ANNALS OF ONCOLOGY, 1998, 9 : 1 - 1
  • [38] ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Pereira, C.
    Pereira, H.
    Silva, C.
    Negreiro, F.
    Queiroga, H.
    Barata, F.
    Almodovar, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 98 - 99
  • [39] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [40] Clinical perspective of afatinib in non-small cell lung cancer
    Chen, Xiaofeng
    Zhu, Quan
    Zhu, Lingjun
    Pei, Dong
    Liu, Yiqian
    Yin, Yongmei
    Schuler, Martin
    Shu, Yongqian
    LUNG CANCER, 2013, 81 (02) : 155 - 161
12345